HRP20230627T1 - Spojevi naftiridinona korisni kao aktivatori t ćelija - Google Patents
Spojevi naftiridinona korisni kao aktivatori t ćelija Download PDFInfo
- Publication number
- HRP20230627T1 HRP20230627T1 HRP20230627TT HRP20230627T HRP20230627T1 HR P20230627 T1 HRP20230627 T1 HR P20230627T1 HR P20230627T T HRP20230627T T HR P20230627TT HR P20230627 T HRP20230627 T HR P20230627T HR P20230627 T1 HRP20230627 T1 HR P20230627T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- piperazin
- dihydro
- oxol
- carbonitrile
- Prior art date
Links
- 229940126530 T cell activator Drugs 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 188
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 183
- -1 2,3-dihydro-1H-indenyl Chemical group 0.000 claims 129
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 38
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000000532 dioxanyl group Chemical group 0.000 claims 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- ULZILYZTLRPDGX-UHFFFAOYSA-N 1-methyl-4-[4-(naphthalen-1-ylmethyl)piperazin-1-yl]-3-nitro-1,5-naphthyridin-2-one Chemical compound CN1C(C(=C(C2=NC=CC=C12)N1CCN(CC1)CC1=CC=CC2=CC=CC=C12)[N+](=O)[O-])=O ULZILYZTLRPDGX-UHFFFAOYSA-N 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- SMOQTQUHFDUWPB-UHFFFAOYSA-N 3-bromo-4-[4-[1-(4-fluorophenyl)ethyl]piperazin-1-yl]-1,6-dimethyl-1,5-naphthyridin-2-one Chemical compound BrC=1C(N(C2=CC=C(N=C2C=1N1CCN(CC1)C(C)C1=CC=C(C=C1)F)C)C)=O SMOQTQUHFDUWPB-UHFFFAOYSA-N 0.000 claims 2
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 2
- UOWGORKPJMDWRZ-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-1-(2-methoxyethyl)-3-nitro-1,5-naphthyridin-2-one Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)CCOC)=O)[N+](=O)[O-])C1=CC=CC=C1 UOWGORKPJMDWRZ-UHFFFAOYSA-N 0.000 claims 2
- YZHOHVUPJZZUKR-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-1-(3-methoxypropyl)-3-nitro-1,5-naphthyridin-2-one Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)CCCOC)=O)[N+](=O)[O-] YZHOHVUPJZZUKR-UHFFFAOYSA-N 0.000 claims 2
- PFKQXAJDIUYYPY-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-1-(4,4-difluorobut-3-enyl)-3-nitro-1,5-naphthyridin-2-one Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)CCC=C(F)F)=O)[N+](=O)[O-] PFKQXAJDIUYYPY-UHFFFAOYSA-N 0.000 claims 2
- FAFGOQMUZVNTRE-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-1-[2-(1,3-dioxan-2-yl)ethyl]-3-nitro-1,5-naphthyridin-2-one Chemical compound O1C(OCCC1)CCN1C(C(=C(C2=NC=CC=C12)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)[N+](=O)[O-])=O FAFGOQMUZVNTRE-UHFFFAOYSA-N 0.000 claims 2
- ZSFGTSDIZIMABR-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-1-butyl-3-nitro-1,5-naphthyridin-2-one Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)CCCC)=O)[N+](=O)[O-] ZSFGTSDIZIMABR-UHFFFAOYSA-N 0.000 claims 2
- IQDWGRZZYIGHSG-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-1-ethyl-3-nitro-1,5-naphthyridin-2-one Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)CC)=O)[N+](=O)[O-])C1=CC=CC=C1 IQDWGRZZYIGHSG-UHFFFAOYSA-N 0.000 claims 2
- NFKOXDDUYBUORT-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)C)=O)[N+](=O)[O-])C1=CC=CC=C1 NFKOXDDUYBUORT-UHFFFAOYSA-N 0.000 claims 2
- XEXMJLISOQCJSF-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-3-nitro-1-(3,3,3-trifluoropropyl)-1,5-naphthyridin-2-one Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)CCC(F)(F)F)=O)[N+](=O)[O-] XEXMJLISOQCJSF-UHFFFAOYSA-N 0.000 claims 2
- DBAMDGDSLWJCOJ-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-3-nitro-1-prop-2-ynyl-1,5-naphthyridin-2-one Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)CC#C)=O)[N+](=O)[O-] DBAMDGDSLWJCOJ-UHFFFAOYSA-N 0.000 claims 2
- ZSQMQGXMHRZHFV-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-3-nitro-1-propyl-1,5-naphthyridin-2-one Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)CCC)=O)[N+](=O)[O-])C1=CC=CC=C1 ZSQMQGXMHRZHFV-UHFFFAOYSA-N 0.000 claims 2
- YTASDDPRPLSTOD-UHFFFAOYSA-N 4-(4-benzhydrylpiperazin-1-yl)-6-bromo-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)N1CCN(CC1)C1=C(C(N(C2=CC=C(N=C12)Br)C)=O)[N+](=O)[O-] YTASDDPRPLSTOD-UHFFFAOYSA-N 0.000 claims 2
- STXZBAJBYKMQGC-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1,6-dimethyl-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=CC(N(C2=CC=C(N=C12)C)C)=O)C1=CC=C(C=C1)F STXZBAJBYKMQGC-UHFFFAOYSA-N 0.000 claims 2
- PVEHLQWSWYKFME-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1,6-dimethyl-3-(trifluoromethyl)-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=C(N=C12)C)C)=O)C(F)(F)F)C1=CC=C(C=C1)F PVEHLQWSWYKFME-UHFFFAOYSA-N 0.000 claims 2
- JOOAQPUKVIIJFX-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-methyl-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=CC(N(C2=CC=CN=C12)C)=O)C1=CC=C(C=C1)F JOOAQPUKVIIJFX-UHFFFAOYSA-N 0.000 claims 2
- KZJLLMSZJHWBHD-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)C)=O)[N+](=O)[O-])C1=CC=C(C=C1)F KZJLLMSZJHWBHD-UHFFFAOYSA-N 0.000 claims 2
- JJYKOMDDIRSCKF-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-3-bromo-1,6-dimethyl-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=C(N=C12)C)C)=O)Br)C1=CC=C(C=C1)F JJYKOMDDIRSCKF-UHFFFAOYSA-N 0.000 claims 2
- ANFWZZKJSSUCSQ-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-3-bromo-1-methyl-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)C)=O)Br)C1=CC=C(C=C1)F ANFWZZKJSSUCSQ-UHFFFAOYSA-N 0.000 claims 2
- NBXPGELZDHHFHA-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-3-chloro-1,6-dimethyl-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=C(N=C12)C)C)=O)Cl)C1=CC=C(C=C1)F NBXPGELZDHHFHA-UHFFFAOYSA-N 0.000 claims 2
- IISCKPGEOFVEBA-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-3-fluoro-1,6-dimethyl-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=C(N=C12)C)C)=O)F)C1=CC=C(C=C1)F IISCKPGEOFVEBA-UHFFFAOYSA-N 0.000 claims 2
- VUYLFBZQBMVRRP-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-6-bromo-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=C(N=C12)Br)C)=O)[N+](=O)[O-])C1=CC=C(C=C1)F VUYLFBZQBMVRRP-UHFFFAOYSA-N 0.000 claims 2
- CICUXUYFDZRQMB-UHFFFAOYSA-N 6-amino-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound NC=1N=C2C(=C(C(N(C2=CC=1)C)=O)[N+](=O)[O-])N1CCN(CC1)C(C1=CC=C(C=C1)F)C1=CC=C(C=C1)F CICUXUYFDZRQMB-UHFFFAOYSA-N 0.000 claims 2
- YXLXKCHFCNKJEC-UHFFFAOYSA-N 6-bromo-1-methyl-4-[4-(naphthalen-1-ylmethyl)piperazin-1-yl]-3-nitro-1,5-naphthyridin-2-one Chemical compound BrC=1N=C2C(=C(C(N(C2=CC=1)C)=O)[N+](=O)[O-])N1CCN(CC1)CC1=CC=CC2=CC=CC=C12 YXLXKCHFCNKJEC-UHFFFAOYSA-N 0.000 claims 2
- JWDODJAKHDACSO-UHFFFAOYSA-N 6-bromo-4-[4-[(4-fluoro-2-hydroxyphenyl)-(4-fluorophenyl)methyl]piperazin-1-yl]-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound BrC=1N=C2C(=C(C(N(C2=CC=1)C)=O)[N+](=O)[O-])N1CCN(CC1)C(C1=CC=C(C=C1)F)C1=C(C=C(C=C1)F)O JWDODJAKHDACSO-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- JWYMPVSNXIMSDP-UHFFFAOYSA-N 3-bromo-4-[4-[(1-ethylindol-4-yl)methyl]piperazin-1-yl]-1-methyl-1,5-naphthyridin-2-one Chemical compound BrC=1C(N(C2=CC=CN=C2C=1N1CCN(CC1)CC1=C2C=CN(C2=CC=C1)CC)C)=O JWYMPVSNXIMSDP-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- CPYALQFCSXVHTN-UHFFFAOYSA-N 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-methyl-3-(2,2,2-trifluoroacetyl)-1,5-naphthyridin-2-one Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C2=CC=CN=C12)C)=O)C(C(F)(F)F)=O)C1=CC=C(C=C1)F CPYALQFCSXVHTN-UHFFFAOYSA-N 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- KITBEADWOVYLAE-UHFFFAOYSA-N 6-bromo-4-[4-[(2-hydroxyphenyl)-(2-methylphenyl)methyl]piperazin-1-yl]-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound BrC=1N=C2C(=C(C(N(C2=CC=1)C)=O)[N+](=O)[O-])N1CCN(CC1)C(C1=C(C=CC=C1)C)C1=C(C=CC=C1)O KITBEADWOVYLAE-UHFFFAOYSA-N 0.000 claims 1
- ZSIRNHYAQRWSHQ-UHFFFAOYSA-N 6-bromo-4-[4-[(2-hydroxyphenyl)-phenylmethyl]piperazin-1-yl]-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound BrC=1N=C2C(=C(C(N(C2=CC=1)C)=O)[N+](=O)[O-])N1CCN(CC1)C(C1=CC=CC=C1)C1=C(C=CC=C1)O ZSIRNHYAQRWSHQ-UHFFFAOYSA-N 0.000 claims 1
- PVCWDXVNDUUZCU-UHFFFAOYSA-N 6-bromo-4-[4-[(4-fluorophenyl)-(2-hydroxyphenyl)methyl]piperazin-1-yl]-1-methyl-3-nitro-1,5-naphthyridin-2-one Chemical compound BrC=1N=C2C(=C(C(N(C2=CC=1)C)=O)[N+](=O)[O-])N1CCN(CC1)C(C1=C(C=CC=C1)O)C1=CC=C(C=C1)F PVCWDXVNDUUZCU-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690444P | 2018-06-27 | 2018-06-27 | |
| EP19740166.4A EP3814347B1 (en) | 2018-06-27 | 2019-06-26 | Naphthyridinone compounds useful as t cell activators |
| PCT/US2019/039131 WO2020006016A1 (en) | 2018-06-27 | 2019-06-26 | Naphthyridinone compounds useful as t cell activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230627T1 true HRP20230627T1 (hr) | 2023-09-29 |
Family
ID=67297314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230627TT HRP20230627T1 (hr) | 2018-06-27 | 2019-06-26 | Spojevi naftiridinona korisni kao aktivatori t ćelija |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11866430B2 (enExample) |
| EP (1) | EP3814347B1 (enExample) |
| JP (1) | JP7373512B2 (enExample) |
| KR (1) | KR102804324B1 (enExample) |
| CN (1) | CN112585139B (enExample) |
| AU (1) | AU2019291792B2 (enExample) |
| BR (1) | BR112020026568A2 (enExample) |
| CA (1) | CA3104647A1 (enExample) |
| CY (1) | CY1126179T1 (enExample) |
| DK (1) | DK3814347T3 (enExample) |
| EA (1) | EA202190137A1 (enExample) |
| ES (1) | ES2950007T3 (enExample) |
| FI (1) | FI3814347T3 (enExample) |
| HR (1) | HRP20230627T1 (enExample) |
| HU (1) | HUE062412T2 (enExample) |
| IL (1) | IL279730B2 (enExample) |
| LT (1) | LT3814347T (enExample) |
| MX (1) | MX2020013373A (enExample) |
| PL (1) | PL3814347T3 (enExample) |
| PT (1) | PT3814347T (enExample) |
| RS (1) | RS64285B1 (enExample) |
| SG (1) | SG11202012973RA (enExample) |
| SI (1) | SI3814347T1 (enExample) |
| SM (1) | SMT202300170T1 (enExample) |
| WO (1) | WO2020006016A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| US20230064809A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| US20230062100A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| CR20220236A (es) | 2019-11-28 | 2022-10-03 | Bayer Pharma AG | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune |
| IL294085A (en) * | 2019-12-19 | 2022-08-01 | Bristol Myers Squibb Co | Combinations of dgk inhibitors and checkpoint antagonists |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CA3162979A1 (en) * | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| BR112022012179A2 (pt) | 2019-12-23 | 2022-09-06 | Bristol Myers Squibb Co | Compostos de quinazolina substituída úteis como ativadores de célula t |
| BR112022012204A2 (pt) * | 2019-12-23 | 2022-09-13 | Bristol Myers Squibb Co | Compostos de heteroarila substituída úteis como ativadores de célula t |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| CN115697980B (zh) * | 2020-04-24 | 2025-03-21 | 拜耳公司 | 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑 |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| KR102682398B1 (ko) * | 2020-11-26 | 2024-07-05 | 주식회사 엘지화학 | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 |
| WO2022133083A1 (en) | 2020-12-16 | 2022-06-23 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| CN117693508A (zh) | 2021-03-03 | 2024-03-12 | 朱诺治疗学股份有限公司 | T细胞疗法和dgk抑制剂的组合 |
| MX2023014762A (es) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) * | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) * | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) * | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023150186A1 (en) * | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2023165528A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| EP4486741A4 (en) | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| US20250215014A1 (en) * | 2022-03-31 | 2025-07-03 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| EP4561561A2 (en) * | 2022-07-29 | 2025-06-04 | Septerna, Inc. | Substituted 3,4-dihydroquinolinone inhibitors of tshr |
| CN119677740A (zh) | 2022-08-09 | 2025-03-21 | 百时美施贵宝公司 | 用作t细胞活化剂的叔胺取代的双环化合物 |
| EP4583876A1 (en) | 2022-09-08 | 2025-07-16 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| WO2025030002A2 (en) * | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2025061020A1 (zh) * | 2023-09-21 | 2025-03-27 | 楚浦创制（武汉）医药科技有限公司 | 苯并五元杂环衍生物及其制备方法与应用、药物组合物 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| BR0312204A (pt) | 2002-06-27 | 2005-04-26 | Schering Ag | Antagonista de receptor ccr5 de quinolina substituìda |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| WO2004087880A2 (en) | 2003-03-26 | 2004-10-14 | Bayer Pharmaceuticals Corporation | Compounds and their use to treat diabetes and related disorders |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| EP1660087A2 (en) | 2003-07-22 | 2006-05-31 | Janssen Pharmaceutica N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| CN1839133A (zh) * | 2003-08-22 | 2006-09-27 | 阿文尼尔药品公司 | 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用 |
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010042489A2 (en) | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| WO2012142498A2 (en) | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR089939A1 (es) | 2012-02-09 | 2014-10-01 | Glenmark Pharmaceuticals Sa | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| US9580443B2 (en) | 2012-11-16 | 2017-02-28 | Merck Patent Gmbh | Heterocyclic derivatives as modulators of kinase activity |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| PT3889145T (pt) | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| US10946020B2 (en) * | 2016-04-06 | 2021-03-16 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| JOP20190086A1 (ar) * | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US12187687B2 (en) | 2017-06-26 | 2025-01-07 | University Of Virginia Patent Foundation | Compositions and uses thereof |
-
2019
- 2019-06-26 CN CN201980055153.7A patent/CN112585139B/zh active Active
- 2019-06-26 DK DK19740166.4T patent/DK3814347T3/da active
- 2019-06-26 LT LTEPPCT/US2019/039131T patent/LT3814347T/lt unknown
- 2019-06-26 KR KR1020217002232A patent/KR102804324B1/ko active Active
- 2019-06-26 HU HUE19740166A patent/HUE062412T2/hu unknown
- 2019-06-26 SG SG11202012973RA patent/SG11202012973RA/en unknown
- 2019-06-26 WO PCT/US2019/039131 patent/WO2020006016A1/en not_active Ceased
- 2019-06-26 ES ES19740166T patent/ES2950007T3/es active Active
- 2019-06-26 MX MX2020013373A patent/MX2020013373A/es unknown
- 2019-06-26 FI FIEP19740166.4T patent/FI3814347T3/fi active
- 2019-06-26 HR HRP20230627TT patent/HRP20230627T1/hr unknown
- 2019-06-26 IL IL279730A patent/IL279730B2/en unknown
- 2019-06-26 PT PT197401664T patent/PT3814347T/pt unknown
- 2019-06-26 JP JP2020572994A patent/JP7373512B2/ja active Active
- 2019-06-26 PL PL19740166.4T patent/PL3814347T3/pl unknown
- 2019-06-26 RS RS20230468A patent/RS64285B1/sr unknown
- 2019-06-26 EA EA202190137A patent/EA202190137A1/ru unknown
- 2019-06-26 BR BR112020026568-3A patent/BR112020026568A2/pt not_active Application Discontinuation
- 2019-06-26 SI SI201930549T patent/SI3814347T1/sl unknown
- 2019-06-26 EP EP19740166.4A patent/EP3814347B1/en active Active
- 2019-06-26 CA CA3104647A patent/CA3104647A1/en active Pending
- 2019-06-26 AU AU2019291792A patent/AU2019291792B2/en not_active Ceased
- 2019-06-26 SM SM20230170T patent/SMT202300170T1/it unknown
- 2019-06-26 US US17/254,914 patent/US11866430B2/en active Active
-
2023
- 2023-07-28 CY CY20231100377T patent/CY1126179T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202012973RA (en) | 2021-01-28 |
| SMT202300170T1 (it) | 2023-09-06 |
| US11866430B2 (en) | 2024-01-09 |
| HUE062412T2 (hu) | 2023-10-28 |
| CA3104647A1 (en) | 2020-01-02 |
| IL279730A (en) | 2021-03-01 |
| US20210277004A1 (en) | 2021-09-09 |
| AU2019291792A1 (en) | 2021-02-11 |
| MX2020013373A (es) | 2021-03-09 |
| WO2020006016A1 (en) | 2020-01-02 |
| CN112585139B (zh) | 2023-12-01 |
| JP2021528469A (ja) | 2021-10-21 |
| KR102804324B1 (ko) | 2025-05-08 |
| SI3814347T1 (sl) | 2023-07-31 |
| IL279730B1 (en) | 2023-08-01 |
| PL3814347T3 (pl) | 2023-07-24 |
| BR112020026568A2 (pt) | 2021-03-23 |
| RS64285B1 (sr) | 2023-07-31 |
| DK3814347T3 (da) | 2023-08-07 |
| IL279730B2 (en) | 2023-12-01 |
| CY1126179T1 (el) | 2026-02-25 |
| EA202190137A1 (ru) | 2021-05-17 |
| AU2019291792B2 (en) | 2022-09-29 |
| CN112585139A (zh) | 2021-03-30 |
| JP7373512B2 (ja) | 2023-11-02 |
| ES2950007T3 (es) | 2023-10-04 |
| EP3814347A1 (en) | 2021-05-05 |
| PT3814347T (pt) | 2023-07-18 |
| FI3814347T3 (fi) | 2023-06-12 |
| EP3814347B1 (en) | 2023-05-03 |
| LT3814347T (lt) | 2023-07-10 |
| KR20210024587A (ko) | 2021-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230627T1 (hr) | Spojevi naftiridinona korisni kao aktivatori t ćelija | |
| JP2021528469A5 (enExample) | ||
| JP2023508052A5 (enExample) | ||
| JP2017533958A5 (enExample) | ||
| HRP20250149T1 (hr) | Supstituirani biciklični derivati peridina korisni kao aktivatori t stanica | |
| ES2450566T3 (es) | Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer | |
| JP2007523152A5 (enExample) | ||
| ES2549529T3 (es) | 4-Aril-N-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| JP5366817B2 (ja) | アリールスルホンアミド化合物 | |
| JP2021529191A5 (enExample) | ||
| CA2493667A1 (en) | Vanilloid receptor ligands and their use in treatments | |
| RU2005124558A (ru) | Производные 1-пропанола и 1-пропиламина и их применение в качестве глюкокортикоидных лигандов | |
| RU2013105490A (ru) | Спироциклические аминовые производные в качестве модуляторов s1p | |
| JP2020524719A5 (enExample) | ||
| CN1659144A (zh) | 喹啉和异喹啉衍生物、其制备方法以及作为炎症抑制剂的应用 | |
| PE20220565A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
| CA2538752A1 (en) | Quinazoline derivatives | |
| CA2522522A1 (en) | Quinazoline compounds | |
| CA2389300A1 (en) | 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
| RU2019136536A (ru) | Ингибиторы гистондеацетилаз (hdac) | |
| CA2682329A1 (en) | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | |
| RU2012106743A (ru) | Производные хромонов, способ их получения и их терапевтические применения | |
| HRP20140478T1 (hr) | Novi derivati (6-okso-1,6-dihidropirimidin-2-il)amida, njihovo dobivanje, te farmaceutska upotreba kao inhibitora fosforilacije akt | |
| JP2005526070A (ja) | オキソ−アザ二環系化合物 | |
| CN1835931A (zh) | 作为cfr拮抗剂的四氢喹唑啉衍生物 |